Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 40Neoplasm Metastasis 7Leiomyosarcoma 7Liposarcoma 6Hemangiosarcoma 6Neurofibrosarcoma 5Sarcoma, Synovial 4Osteosarcoma 4Histiocytoma, Malignant Fibrous 4Glioblastoma 4Dermatofibrosarcoma 4Chondrosarcoma, Extraskeletal Myxoid 4Sarcoma, Alveolar Soft Part 3Neoplasms 3Gliosarcoma 3Gastrointestinal Stromal Tumors 3Fibrosarcoma 3Breast Neoplasms 3Brain Neoplasms 3Solitary Fibrous Tumors 2Sarcoma, Clear Cell 2Rhabdomyosarcoma 2Recurrence 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Nerve Sheath Neoplasms 2Histiocytoma, Angiomatoid Fibrous 2Hemangioendothelioma, Epithelioid 2Granuloma, Plasma Cell 2Carcinoma, Renal Cell 2

Interventions

Docetaxel 2pazopanib 1lentiviral minigene vaccine of COVID-19 coronavirus 1Gemcitabine 1Bevacizumab 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Histiocytoma × pazopanib × Sarcoma × Clear all
NCT01418001 2018-01-11

Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)

Memorial Sloan Kettering Cancer Center

Phase 1/2 Terminated
5 enrolled 6 charts
Sarcoma

Leiomyosarcoma, Sarcoma, Neurofibrosarcoma, Histiocytoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡